Stranger things have happened, I do think AGGX has IP which may be of value to another company with better financing and the inclination to move it through clinical trials. If not a buyout, the best way forward would be for management to buy a clean shell and do a reverse-merger where AGGX shareholders get shares of the new controlling entity.
News 
Market Data 
Discover 
